Using Phosphine Ligands with a Biological Role to Modulate Reactivity in Novel Platinum Complexes

Overview

Journal R Soc Open Sci

Specialty Science

Date 2018 Mar 9

PMID 29515851

Citations 1

Authors

Marcelo Echeverri

Amparo Alvarez-Valdes

Francisco Navas

Josefina Perles

Isabel Sanchez-Perez

A G Quiroga

Affiliations

Soon will be listed here.

Abstract

Three platinum complexes with and configuration -[Pt(TCEP)Cl], -[Pt(tmTCEP)Cl] and -[Pt(TCEP)Cl], where TCEP is tris(2-carboxyethyl)phosphine, have been synthesized and fully characterized by usual techniques including single-crystal X-ray diffraction for -[Pt(TCEP)Cl] and -[Pt(tmTCEP)Cl]. Here, we also report on an esterification process of TCEP, which takes place in the presence of alcohols, leading to a platinum complex coordinated to an ester tmTCEP (2-methoxycarbonylethyl phosphine) ligand. The stability in solution of the three compounds and their interaction with biological models such as DNA (pBR322 and calf thymus DNA) and proteins (lysozyme and RNase) have also been studied.

Citing Articles

Pentafluorophenyl Platinum(II) Complexes of PTA and its N-Allyl and N-Benzyl Derivatives: Synthesis, Characterization and Biological Activity.

Sgarbossa P, Sliwinska-Hill U, Guedes da Ilva M, Bazanow B, Pawlak A, Jackulak N Materials (Basel). 2019; 12(23).

PMID: 31779206 PMC: 6926962. DOI: 10.3390/ma12233907.

References

Muller A . trans-Bis(benzyl-diphenyl-phosphane-κP)dichloridoplatinum(II). Acta Crystallogr Sect E Struct Rep Online. 2013; 68(Pt 12):m1512. PMC: 3588759. DOI: 10.1107/S160053681204696X. View

Johnstone T, Wilson J, Lippard S . Monofunctional and higher-valent platinum anticancer agents. Inorg Chem. 2013; 52(21):12234-49. PMC: 3818431. DOI: 10.1021/ic400538c. View

Nakamoto K, Tsuboi M, Strahan G . Drug-DNA interactions: structures and spectra. Methods Biochem Anal. 2009; 51:1-366. View

Casini A, Mastrobuoni G, Temperini C, Gabbiani C, Francese S, Moneti G . ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. Chem Commun (Camb). 2006; (2):156-8. DOI: 10.1039/b611122j. View

Montero E, Diaz S, Gonzalez-Vadillo A, Perez J, Alonso C, Navarro-Ranninger C . Preparation and characterization of novel trans-[PtCl(2)(amine)(isopropylamine)] compounds: cytotoxic activity and apoptosis induction in ras-transformed cells. J Med Chem. 1999; 42(20):4264-8. DOI: 10.1021/jm991015e. View

Bednarski P, Mackay F, Sadler P . Photoactivatable platinum complexes. Anticancer Agents Med Chem. 2007; 7(1):75-93. DOI: 10.2174/187152007779314053. View

Boal A, Rosenzweig A . Crystal structures of cisplatin bound to a human copper chaperone. J Am Chem Soc. 2009; 131(40):14196-7. PMC: 2760026. DOI: 10.1021/ja906363t. View

Gothe Y, Marzo T, Messori L, Metzler-Nolte N . Cytotoxic activity and protein binding through an unusual oxidative mechanism by an iridium(I)-NHC complex. Chem Commun (Camb). 2015; 51(15):3151-3. DOI: 10.1039/c4cc10014j. View

Cheung-Ong K, Song K, Ma Z, Shabtai D, Lee A, Gallo D . Comparative chemogenomics to examine the mechanism of action of dna-targeted platinum-acridine anticancer agents. ACS Chem Biol. 2012; 7(11):1892-901. PMC: 3500413. DOI: 10.1021/cb300320d. View

10.

Medrano M, Alvarez-Valdes A, Perles J, Lloret-Fillol J, Munoz-Galvan S, Carnero A . Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs. Chem Commun (Camb). 2013; 49(42):4806-8. DOI: 10.1039/c3cc38416k. View

11.

Garcia-Cano J, Ambroise G, Pascual-Serra R, Carrion M, Serrano-Oviedo L, Ortega-Muelas M . Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance. Oncotarget. 2015; 6(17):15551-65. PMC: 4558170. DOI: 10.18632/oncotarget.3902. View

12.

Gutierrez-Gonzalez A, Belda-Iniesta C, Bargiela-Iparraguirre J, Dominguez G, Garcia Alfonso P, Perona R . Targeting Chk2 improves gastric cancer chemotherapy by impairing DNA damage repair. Apoptosis. 2012; 18(3):347-60. DOI: 10.1007/s10495-012-0794-2. View

13.

Cline D, Redding S, Brohawn S, Psathas J, Schneider J, Thorpe C . New water-soluble phosphines as reductants of peptide and protein disulfide bonds: reactivity and membrane permeability. Biochemistry. 2004; 43(48):15195-203. DOI: 10.1021/bi048329a. View

14.

Herrera J, Mendes F, Gama S, Santos I, Navarro Ranninger C, Cabrera S . Design and biological evaluation of new platinum(II) complexes bearing ligands with DNA-targeting ability. Inorg Chem. 2014; 53(23):12627-34. DOI: 10.1021/ic502373n. View

15.

Johnstone T, Suntharalingam K, Lippard S . The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem Rev. 2016; 116(5):3436-86. PMC: 4792284. DOI: 10.1021/acs.chemrev.5b00597. View

16.

Pruchnik H, Kral T, Hof M . Interaction of Newly Platinum(II) with Tris(2-carboxyethyl)phosphine Complex with DNA and Model Lipid Membrane. J Membr Biol. 2017; 250(5):461-470. PMC: 5613069. DOI: 10.1007/s00232-017-9972-z. View

17.

Wenzel M, Meier-Menches S, Williams T, Ramisch E, Barone G, Casini A . Selective targeting of PARP-1 zinc finger recognition domains with Au(iii) organometallics. Chem Commun (Camb). 2018; 54(6):611-614. DOI: 10.1039/c7cc08406d. View

18.

Messori L, Merlino A . Cisplatin binding to proteins: molecular structure of the ribonuclease a adduct. Inorg Chem. 2014; 53(8):3929-31. DOI: 10.1021/ic500360f. View

19.

Palm-Espling M, Lundin C, Bjorn E, Naredi P, Wittung-Stafshede P . Interaction between the anticancer drug Cisplatin and the copper chaperone Atox1 in human melanoma cells. Protein Pept Lett. 2013; 21(1):63-8. DOI: 10.2174/09298665113209990036. View

20.

Aris S, Farrell N . Towards Antitumor Active trans-Platinum Compounds. Eur J Inorg Chem. 2010; 2009(10):1293. PMC: 2821104. DOI: 10.1002/ejic.200801118. View